View The Lancet Oncology summary as HTML or PDF
French version of The Lancet Oncology summary (hosted by Centre Léon Bérard)
This volume of the IARC Monographs provides an assessment of the carcinogenicity of 14 drugs and herbal products.
The IARC Monographs Working Group relied mainly on epidemiological studies to evaluate the carcinogenic hazard to humans exposed to the drugs digoxin (widely prescribed for the treatment of chronic heart failure), pioglitazone (used for the treatment of type 2 diabetes mellitus), and hydrochlorothiazide (used to treat hypertension).
Other agents evaluated included the drugs primidone, sulfasalazine, pentosan polysulfate sodium, and triamterene, and five herbal products (or their components): Aloe vera whole leaf extract, goldenseal root powder, Ginkgo biloba leaf extract, kava extract, and pulegone. In view of the limited agent-specific information available from epidemiological studies, assessments of these agents relied mainly on carcinogenicity bioassays to reach conclusions as to the carcinogenic hazard to exposed humans.
Contents and Note to the Reader
List of Participants
List of Abbreviations
Pioglitazone and rosiglitazone